Direct comparison of low- and mid-frequency Raman spectroscopy for quantitative solid-state pharmaceutical analysis

Tiina Lipiäinen, Sara J. Fraser-Miller, Keith C. Gordon, Clare J. Strachan

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)

Abstract

This study considers the potential of low-frequency (terahertz) Raman spectroscopy in the quantitative analysis of ternary mixtures of solid-state forms. Direct comparison between low-frequency and mid-frequency spectral regions for quantitative analysis of crystal form mixtures, without confounding sampling and instrumental variations, is reported for the first time. Piroxicam was used as a model drug, and the low-frequency spectra of piroxicam forms β α2 and monohydrate are presented for the first time. These forms show clear spectral differences in both the low- and mid-frequency regions. Both spectral regions provided quantitative models suitable for predicting the mixture compositions using partial least squares regression (PLSR), but the low-frequency data gave better models, based on lower errors of prediction (2.7, 3.1 and 3.2% root-mean-square errors of prediction [RMSEP] values for the β α2 and monohydrate forms, respectively) than the mid-frequency data (6.3, 5.4 and 4.8%, for the β α2 and monohydrate forms, respectively). The better performance of low-frequency Raman analysis was attributed to larger spectral differences between the solid-state forms, combined with a higher signal-to-noise ratio.
Original languageEnglish
Pages (from-to)343-350
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume149
DOIs
Publication statusPublished - 5 Feb 2018
Externally publishedYes

Keywords

  • Crystal form mixture
  • Low-frequency Raman spectroscopy
  • Piroxicam
  • Quantitative analysis
  • Solid-state
  • Terahertz Raman spectroscopy
  • Anti-Inflammatory Agents, Non-Steroidal

Fingerprint

Dive into the research topics of 'Direct comparison of low- and mid-frequency Raman spectroscopy for quantitative solid-state pharmaceutical analysis'. Together they form a unique fingerprint.

Cite this